Broadhurst Jeffrey B Acquires New Position in Globus Medical, Inc. $GMED

Broadhurst Jeffrey B acquired a new stake in Globus Medical, Inc. (NYSE:GMED) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 23,053 shares of the medical device company’s stock, valued at approximately $1,986,000. Globus Medical comprises about 2.0% of Broadhurst Jeffrey B’s portfolio, making the stock its 20th biggest position.

A number of other institutional investors have also recently bought and sold shares of the business. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC increased its holdings in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the period. Parallel Advisors LLC lifted its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. Finally, Headlands Technologies LLC boosted its holdings in Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after buying an additional 631 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on GMED. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus decreased their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Finally, BMO Capital Markets assumed coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $103.75.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is owned by corporate insiders.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $76.46 on Friday. The firm has a market cap of $10.38 billion, a price-to-earnings ratio of 17.78, a price-to-earnings-growth ratio of 1.56 and a beta of 0.95. The stock’s 50-day moving average is $79.79 and its 200-day moving average is $86.06. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period last year, the company earned $0.68 earnings per share. Globus Medical’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.